SUMMARY DAY 1 AND OVERVIEW DAY 2

Meg Doherty . Global HIV, Hepatitis and STI Programmes, WHO
TURN ON YOUR CAMERA AND SMILE
Summary Day 1 – Inspiration to do more together

Quotable quotes:
‘COVID19 has exposed the plight of the poor and challenges us to re-engage for the cure of the virus but also for cure for social injustice, and the lack of access to public health care... We need to protect children from all forms of exclusion...’ - Cardinal Turkson

‘Power of collaboration and the Vatican – has moved us much further than if we did this alone’ - Amb Deborah Birx

‘We must use the families to find all the children left behind’ - Shannon Hader

‘Must push forward to achieve our 2020 HIV &TB HLM targets; and to catch up’ Lucica Ditiu

‘The Vatican dialogue has held us all accountable...’ - Chip Lyons

‘Finally we are speaking about optimization of paediatric treatments...missing children are missing lives .. It is not missing healthy life years – it is missing lives that are healthy’ -Maurine Murenga

‘When all is said and done, let’s have more done than said’ - Mariangela Simao

‘Proud to be part of the ‘coalition of the good’ - Father Bob Vitillo
Encourage utilization of a shared and integrated diagnostic network; as well as multiple assay capacity on current devices.

For both HIV and TB, all-inclusive, transparent pricing for both lab and POC technologies is key to ensuring access to diagnostic and monitoring assays.

Continue to develop new devices and assays, including a new, more sensitive urine LF-LAM for children, TB tests on devices already capable of HIV (and other) testing, use of alternative non-sputum specimens (ie stool, blood) for TB testing, plasma separation card for HIV viral load access expansion.

Continue and complete studies of using oral-based tests by caregivers to support WHO guidance development, including impact, feasibility, and acceptability data.

Strengthen collaboration between product developers and end users so new products can be rapidly taken up.

Increased funding necessary to expand interventions and ensure procurement of new diagnostic innovations.
Summary Day 1 – Medicines R&D Commitments

- For HIV - **focus should be on finishing the business** & work to accelerate R&D of ARVs with potential
- For TB - **optimize the way studies are designed and implemented** and the urgent need to promote **stronger focus and partnership across stakeholders**
- **Policymakers will continue to update their normative work** to capture new developments and support prioritization of research and development
- Research networks to **optimize and accelerate investigation of new drugs for infants and children across the two diseases**; exciting new partnership with industry, donors and other stakeholders
- Industry partners have **committed to promising partnerships** & will accelerate and optimize their Paediatric development plans
- Key donors such as Unitaid to continue and **expand their investments to support development of better formulations for children**
- From TAG – **call that all TB R&D commit 1% of funding to develop paediatric formulations**
- **Expand CT sites for TB paeds trials**; parallel rather than serial pathways
- **CS calls to be involved in the design and implementation of R&D**; plan access during R&D
Overview Day 2

- Solutions & actions on global, regional, and national regulatory processes for medicines and diagnostics for children (HIV and TB)
- Solutions & actions on identifying and diagnosing children (HIV and TB)
- Solutions & actions on introduction and scale-up of medicines for children (HIV and TB)
- Review of commitments on diagnostics and medicines and accountability framework
- Conclusion and way forward